argenx SE (MEX:ARGX) Long-Term Capital Lease Obligation : MXN0 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is argenx SE Long-Term Capital Lease Obligation?

argenx SE's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was MXN0 Mil.

argenx SE's quarterly Long-Term Capital Lease Obligation increased from Sep. 2024 (MXN0 Mil) to Dec. 2024 (MXN678 Mil) but then declined from Dec. 2024 (MXN678 Mil) to Mar. 2025 (MXN0 Mil).

argenx SE's annual Long-Term Capital Lease Obligation increased from Dec. 2022 (MXN176 Mil) to Dec. 2023 (MXN261 Mil) and increased from Dec. 2023 (MXN261 Mil) to Dec. 2024 (MXN678 Mil).

argenx SE Long-Term Capital Lease Obligation Historical Data

The historical data trend for argenx SE's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Long-Term Capital Lease Obligation Chart

argenx SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

122.95

163.21

175.64

260.62

678.23

argenx SE Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	514.92	-	678.23	-

argenx SE (MEX:ARGX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

argenx SE Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of argenx SE's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (MEX:ARGX) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.